Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

Shares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the ...

Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi wins ‘Top GCC of 2025’ and ‘GCC Country Leader of the Year’ at Zyoin Group workplace summit and awards 2025: Our Bureau, Bengaluru Monday, July 14, 2025, 15:30 Hrs ...

Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 10 and set a price target of €95.00. The company’s shares closed yesterday at $98.70. Elevat ...

Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...

Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...

Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...